Johannes A. M. Christiaans

Johannes A. M. Christiaans

Auto-generated profile, based on publicly available information

Johannes A. M. Christiaans

Department of Radiology & Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EJElina M. Jarho
Elina M. Jarho
JVJarkko I. Venäläinen
Jarkko I. Venäläinen
JHJuhani Huuskonen
Juhani Huuskonen
JCJohannes A. M. Christiaans
Johannes A. M. Christiaans
JGJ.Arturo García-Horsman
J.Arturo García-Horsman
EWErik A. A. Wallén
Erik A. A. Wallén

1 February 2006 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JVJarkko I. Venäläinen
Jarkko I. Venäläinen
JGJ.Arturo García-Horsman
J.Arturo García-Horsman
MFMarkus M. Forsberg
Markus M. Forsberg
AJAaro Jalkanen
Aaro Jalkanen
EWErik A.A. Wallén
Erik A.A. Wallén
PMPekka T. Männistö
Pekka T. Männistö

13 March 1999 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JKJari T. Kovalainen
Jari T. Kovalainen
JCJohannes A. M. Christiaans
Johannes A. M. Christiaans
SKSanna Kotisaari
Sanna Kotisaari
JLJarmo T. Laitinen
Jarmo T. Laitinen
PMPekka T. Männistö
Pekka T. Männistö
JGJukka Gynther
Jukka Gynther

1 July 2002 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
EWErik A.A Wallén
Erik A.A Wallén
JCJohannes A.M Christiaans
Johannes A.M Christiaans
SSSusanna M Saario
Susanna M Saario
MFMarkus M Forsberg
Markus M Forsberg
JVJarkko I Venäläinen
Jarkko I Venäläinen
JGJukka Gynther
Jukka Gynther

27 August 2002 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EWErik A. A. Wallén
Erik A. A. Wallén
JCJohannes A. M. Christiaans
Johannes A. M. Christiaans
MFMarkus M. Forsberg
Markus M. Forsberg
JVJarkko I. Venäläinen
Jarkko I. Venäläinen
PMPekka T. Männistö
Pekka T. Männistö
JGJukka Gynther
Jukka Gynther

7 September 2004 in Biochemical Journal
Verified
Journal Article
Closed access
JVJarkko I. Venäläinen
Jarkko I. Venäläinen
RJRisto O. Juvonen
Risto O. Juvonen
JGJ.Arturo García-Horsman
J.Arturo García-Horsman
EWErik A. A. Wallén
Erik A. A. Wallén
JCJohannes A. M. Christiaans
Johannes A. M. Christiaans
PMPekka T. Männistö
Pekka T. Männistö
POP (prolyl oligopeptidase) specifically hydrolyses a number of small proline-containing peptides at the carboxy end of the proline residue and POP inhibitors have been shown to have cognition-enhancing properties. It has been noted that certain functional groups at the P1 site of the inhibitor, which correspond to the substrate residue on the N-terminal side of the bond to be cleaved, increase the inhibitory potency. However, detailed mechanistic and kinetic analysis of the inhibition has not been studied. In the present study, we examined the effect of different functional groups at the P1 site of the parent inhibitor isophthalic acid bis-(L-prolylpyrrolidine) amide on the binding kinetics to POP. Addition of CHO, CN or COCH2OH groups to the P1 site increased the inhibitory potency by two orders of magnitude (Ki=11.8–0.1 nM) and caused a clear slow-binding inhibition. The inhibitor containing a CHO group had the lowest association rate constant, kon=(2.43±0.12)×105 M−1·s−1, whereas the inhibitor with a CN group exhibited the fastest binding, kon=(12.0±0.08)×105 M−1·s−1. In addition, the dissociation rate was found to be crucially dependent on the type of the functional group. Compounds with COCH2OH and CHO groups had much longer half-lives of dissociation (over 5 h) compared with the compound with the CN group (25 min), although the Ki values of the compounds were relatively similar. A possibility to optimize the duration of inhibition by changing the functional group at the P1 site is important when planning therapeutically useful POP inhibitors.